Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 16.36% and 5.97%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More

by Indrajit Bandyopadhyay

Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.

Zacks Equity Research

3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HSIC vs. MMSI: Which Stock Is the Better Value Option?

Zacks Equity Research

Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Zacks Equity Research

SmileDirectClub (SDC) Down 25.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

SmileDirectClub (SDC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Merit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Merit Medical's (MMSI) New Launch to Boost its Product Suite

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger

by Zacks Equity Research

CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.

Zacks Equity Research

IDEXX (IDXX) Global Sales, Instrument Placement Robust

by Zacks Equity Research

IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.

Zacks Equity Research

MMSI vs. WST: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its Cardiovascular segment and the majority of product categories within its Cardiovascular unit.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 17.91% and 1.26%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails

by Zacks Equity Research

Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of -6.67% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up

by Zacks Equity Research

Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.

Zacks Equity Research

Medtronic (MDT) Receives CE Mark Approval For Aurora System

by Zacks Equity Research

Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.

Debanjana Dey headshot

MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More

by Debanjana Dey

MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.

Zacks Equity Research

Reasons to Retain Patterson Companies (PDCO) Stock Now

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.